|
MYC Program as a biomarker of response to treatment with Enzalutamide
Invention Summary:
Administration of Enzalutamide has been shown to improve patient survival overall, yet patients respond differently to the drug with nearly half either not responding or developing resistance over time. Unfortunately, patients that fail Enzalutamide treatment are left with no targeted therapeutic option, and progress to...
Published: 10/11/2024
|
Inventor(s):
Keywords(s):
Category(s): Technology Classifications > Cancer, Technology Classifications > Diagnostics, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Bioinformatic Methods for Determining Resistance to Cancer Treatments
Invention Summary:
Determining resistance to chemotherapy treatments for specific types of cancer (e.g., prostate, lung, breast, etc.,) as early as possible can prolong patients' lives by enabling them to be treated with other, and hopefully, more effective treatments as soon as possible.
Researchers at Rutgers University have...
Published: 7/15/2024
|
Inventor(s): Antonina Mitrofanova, Sukanya Panja, Sarki Abdulkadir, Vishal Kothari, Edward Schaeffer
Keywords(s): Bioinformatics, Biomarkers, Digital Health, Prostate Cancer
Category(s): Technology Classifications > Software & Copyright, Technology Classifications > Software & Algorithms, Technology Classifications > Cancer, Technology Classifications > Healthcare & Life Sciences
|
|
A novel inhibitory mimetic peptide
slows down tumor development
Inhibitory peptide increases caspase3 activity (A) by blocking GC1/Trx1 complex thereby limiting cell proliferation by inducing cell death (B).
Invention Summary:
Soluble guanylyl cyclase (GC1) and thioredoxin 1 (Trx1), when physically interacting and attaching to each other, they acquire the ability to induce changes in other target...
Published: 7/22/2024
|
Inventor(s): Annie Beuve
Keywords(s): Anti-cancer
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Cancer
|
|
Off-the-Shelf CAR-Macrophages for Solid Tumors
Invention Summary:
Chimeric Antigen Receptor (CAR) therapy requires isolation of the respective immune cells from the patient’s blood, genetic manipulation, and infusion of the modified cells back into the patient’s body. This makes it personalized and effective but expensive. The CAR-T (modified T cells) therapy has shown...
Published: 1/11/2024
|
Inventor(s): Pingping Hou
Keywords(s): Anti-cancer
Category(s): Technology Classifications > Cell Therapy, Technology Classifications > Cancer, Technology Classifications > Healthcare & Life Sciences
|
|
Methods of diagnosing B cell malignancies and detecting B cell malignancy relapse
Workflow schematic of the diagnostic platform for detecting B cell malignancies.
Invention Summary:
B cell malignancies comprise more than 50% of blood cancers and approximately 90% of all lymphomas. Existing technologies for the detection of B cell malignancies include modern imaging technologies, flow cytometry of B cell subpopulations, cytogenetic...
Published: 8/19/2024
|
Inventor(s): Ping Xie, Jaeyong Jung, Roger Strair, Samantha Gokhale, Lauri Goodell, Amer Assal
Keywords(s): Cancer biomarkers
Category(s): Technology Classifications > Diagnostics, Technology Classifications > Cancer, Technology Classifications > Healthcare & Life Sciences
|
|
DEVELOPMENT OF SPECIFIC CRK-LIKE ADAPTOR PROTEIN INHIBITORS FOR CANCER THERAPY
NC5 inhibits tumor growth and prolongs survival in vivo. NC5 treatment inhibits TNBC tumor growth and prolongs mice survival in xenograft and PDX mouse models. (A) Survival of mice bearing MDA-MB-231-Luc orthotopic xenograft tumors following treatment with vehicle (black line), Gleevec (blue line), or NC5 (red line). (B) Survival of mice bearing PDX...
Published: 7/31/2024
|
Inventor(s): Dongfang Liu, Xuening Wang, Jacques Roberge
Keywords(s): Anti-cancer, Proteins
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Cancer
|
|
Expanding Human Primary Liver Tissues into Functional Organoids
Invention Summary:
Chronic liver diseases account for approximately two million deaths per year- one million due to complications of cirrhosis and one million due to viral hepatitis and hepatocellular carcinoma. Unfortunately, there are few treatment options for these conditions, and they commonly require organ transplants. The primary...
Published: 5/2/2024
|
Inventor(s): Hatim Sabaawy, Fredric Wondisford
Keywords(s): Drug Discovery/Screening
Category(s): Technology Classifications > Cancer, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
SAHMI: Microbiome-based screening method for cancer and other diseases
Screening methodology and principle data identifying differences in
microbiome diversity from disease state in pancreatic cancer
Invention Summary:
The microbiome plays an essential role in the prognosis and progression of disease and health, as seen in cancers like pancreatic cancer. Pancreatic cancer is rising in majority of cancer...
Published: 8/8/2022
|
Inventor(s): Subhajyoti De, Bassel Ghaddar
Keywords(s): Anti-cancer, Bioinformatics, Biomarkers, Cancer biomarkers
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Diagnostics, Technology Classifications > Cancer
|
|
Combined Opioidergic and Beta-Adrenergic Drugs for
Cancer and Immune Diseases
Figure 1. (Left) Combined, synergistic treatment with naltrexone (NTX), propranolol (PRO), and Anti-PD1 antibody shows decrease in tumor size, by volume. (Right) Combined treatment of NTX, DPDPE, and PRO similarly decreases tumor size compared to controls.
Invention Summary:
One of the major cancer therapy approaches that is being...
Published: 5/8/2024
|
Inventor(s): Dipak Sarkar
Keywords(s): Anti-cancer, Small molecules
Category(s): Technology Classifications > Cancer, Technology Classifications > Healthcare & Life Sciences
|
|
Biomarkers for Identifying Patients at High Risk of Progressing
from Barrett’s Esophagus to Esophageal Adenocarcinoma
Invention Summary:
Esophageal adenocarcinoma (EAC) has a poor prognosis with a 5-year overall survival of 15-20%. In the past 3 decades, the incidence of EAC increased 600-800%. Barrett’s esophagus (BE), the precancerous lesion for EAC, has approximately 0.11 to 1.6% annual rate of progression to EAC. Currently, the guidelines for BE surveillance...
Published: 5/8/2024
|
Inventor(s): Zhongren ("David") Zhou
Keywords(s): Anti-cancer, Biomarkers, Cancer biomarkers
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Diagnostics, Technology Classifications > Cancer
|
